Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Licensing Opportunities

Investor Relations

View Investor Relations

Latest News

Ligand to Acquire Crystal Bioscience, the Leader in Chicken-derived Fully-human Antibody Generation, for $25 Million in Cash plus Additional Potential Payments

Read More

Ligand to Host Analyst Day on November 14th in New York City

Read More

Ligand Announces Top-Line Results from Phase 2 Study of LGD-6972 in Patients with Type 2 Diabetes

Read More

Recent Events

Upcoming Events

Stock Snapshot

Market Cap
Day Range
52-Week Range